Skip to main content

TRAP-seq identifies cystine/glutamate antiporter as a driver of recovery from liver injury.

Citation
Wang, A. W., et al. “Trap-Seq Identifies Cystine/Glutamate Antiporter As A Driver Of Recovery From Liver Injury.”. The Journal Of Clinical Investigation, pp. 2297-2309.
Center University of Pennsylvania
Author Amber W Wang, Kirk J Wangensteen, Yue J Wang, Adam M Zahm, Nicholas G Moss, Noam Erez, Klaus H Kaestner
Keywords Expression profiling, Gastroenterology, Hepatology, Molecular genetics, Mouse models
Abstract

Understanding the molecular basis of the regenerative response following hepatic injury holds promise for improved treatment of liver diseases. Here, we report an innovative method to profile gene expression specifically in the hepatocytes that regenerate the liver following toxic injury. We used the Fah-/- mouse, a model of hereditary tyrosinemia, which conditionally undergoes severe liver injury unless fumarylacetoacetate hydrolase (FAH) expression is reconstituted ectopically. We used translating ribosome affinity purification followed by high-throughput RNA sequencing (TRAP-seq) to isolate mRNAs specific to repopulating hepatocytes. We uncovered upstream regulators and important signaling pathways that are highly enriched in genes changed in regenerating hepatocytes. Specifically, we found that glutathione metabolism, particularly the gene Slc7a11 encoding the cystine/glutamate antiporter (xCT), is massively upregulated during liver regeneration. Furthermore, we show that Slc7a11 overexpression in hepatocytes enhances, and its suppression inhibits, repopulation following toxic injury. TRAP-seq allows cell type-specific expression profiling in repopulating hepatocytes and identified xCT, a factor that supports antioxidant responses during liver regeneration. xCT has potential as a therapeutic target for enhancing liver regeneration in response to liver injury.

Year of Publication
2018
Journal
The Journal of clinical investigation
Volume
128
Issue
6
Number of Pages
2297-2309
Date Published
12/2018
ISSN Number
1558-8238
DOI
10.1172/JCI95120
Alternate Journal
J. Clin. Invest.
PMID
29517978
PMCID
PMC5983312
Download citation